RxDoctor Payments DataLook up a doctor →

George Fadda, MD

Nephrology · la Mesa, CANPI 1619972247

Payments from drug & device makers

$2,118,790in general payments, 2019–2025

Across 900 payments — averaging $2354.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$538K
  • Kadmon Corporation LLC$379K
  • Astrazeneca UK Limited$320K
  • GSK$267K
  • Akebia Therapeutics Inc$137K
  • CSL Behring$128K
  • plus $350K from 30 others
$218in research payments, 2019–2025

Across 3 payments — averaging $72.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$218

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,118,790 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$437,531
Medicare patients
731
Services billed
3,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →